CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

Carmen Jeffrey Del, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 14,337 Common Stock, par value $0.001 per share at $31.50 ($451,616) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 150,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 200,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 135,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 88,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 167,918 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 137,553 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 106,873 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 8,039 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 11,206 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 32,257 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Carmen Jeffrey Del — Officer (Chief Commercial Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share14,337$32$451.6K0
2026-07-15Disposition to the issuerOptions to purchase common stock150,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock200,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock135,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock88,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock167,918——0
2026-07-15Disposition to the issuerOptions to purchase common stock137,553——0
2026-07-15Disposition to the issuerOptions to purchase common stock106,873——0
2026-07-15Disposition to the issuerRestricted Stock Units8,039——0
2026-07-15Disposition to the issuerRestricted Stock Units11,206——0
2026-07-15Disposition to the issuerRestricted Stock Units32,257——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (14,337 shares)
2026-07-15Disposition to the issuer (150,000 shares)
2026-07-15Disposition to the issuer (200,000 shares)
2026-07-15Disposition to the issuer (135,000 shares)
2026-07-15Disposition to the issuer (88,000 shares)
2026-07-15Disposition to the issuer (167,918 shares)
2026-07-15Disposition to the issuer (137,553 shares)
2026-07-15Disposition to the issuer (106,873 shares)
2026-07-15Disposition to the issuer (8,039 shares)
2026-07-15Disposition to the issuer (11,206 shares)
2026-07-15Disposition to the issuer (32,257 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Carmen Jeffrey Del

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.